XML 23 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenues:    
Research and development revenue $ 3,495,389 $ 2,898,806
Costs and expenses:    
Costs of research and development revenue 1,194,624 1,975,849
Research and development 2,044,253 3,297,266
General and administrative 6,134,773 5,817,013
Foreign currency exchange loss 22,561 38,417
Total costs and expenses 9,396,211 11,128,545
Loss from operations (5,900,822) (8,229,739)
Other income (expense):    
Interest income 456,992 416,686
Gain on sale of Alphazyme 62,642 1,017,592
Total other income (expense), net 91,663 1,434,278
Net loss $ (5,809,159) $ (6,795,461)
Basic and diluted net loss per common share (in dollars per share) $ (0.2) $ (0.24)
Basic and diluted weighted-average common shares outstanding (in shares) 29,318,123 28,798,833
Nonrelated Party [Member]    
Other income (expense):    
Interest expense $ (288,142) $ 0
Related Party [Member]    
Other income (expense):    
Interest expense (139,829) 0
Research and Development [Member]    
Revenues:    
Research and development revenue 1,605,220 2,545,865
License [Member]    
Revenues:    
Research and development revenue $ 1,890,169 $ 352,941